Licensing
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global pharma market opportunities. Get expert insights on drug licensing deals, IP strategies, and M&A trends for strategic BD.
Showing 1–12 of 59 articles
Quick answer
NovaPharmaNews Licensing hub for FDA covers 59 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Socioeconomic status shapes children’s brain development, study finds
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
AstraZeneca expands obesity push as it invests $125M in ultrasound medicine
Tillomed Laboratories update: pipeline, melphalan and next catalysts
Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
Sanofi completes Inhibrx acquisition for $1.7B
McGuireWoods' Alyssa Campbell Honored in M&A Advisor Emerging Leaders Awards
Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
China: The Innovation Factor – Implications for Pharma BD and Investors
Utah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma
Mercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.